Evidence map›Paper›PMID 40624873›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2025

Circulating Tumor Tissue-Modified-Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer.

Jaclyn Lee, Ashtyn McAdoo, Carly Fassler, Tianyi Sun, Dandan Liu, Natalie Lockney, Ryan Whitaker, Michael C Topf, Kyle Mannion

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jaclyn LeeDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ashtyn McAdooDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Carly FasslerBrody School of Medicine, East Carolina University, Greenville, South Carolina, USA.
Tianyi SunDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Dandan LiuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Natalie LockneyDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ryan WhitakerDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Michael C TopfDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-1022-4417
Kyle MannionDepartment of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
Augmented Reality to Guide Head and Neck Cancer SurgeryK08CA293255 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Michael Topf · 2024 to 2026
$645k
NCI NIH HHS K08 CA293255NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

introductionTumor-tissue modified viral (TTMV)-human papillomavirus (HPV) DNA is an increasingly utilized biomarker for patients with HPV-mediated oropharyngeal squamous cell carcinoma (OPSCC). However, much remains to be studied regarding the quantitative importance of a positive pre-treatment result and correlations with disease burden. STUDY

designRetrospective cohort study.

settingSingle tertiary care center; January 2022 to July 2024.

methodsPatients with HPV-associated OPSCC and baseline pre-treatment TTMV-HPV DNA levels were evaluated for primary tumor and lymph node disease extent on clinical imaging, exam, and surgical pathology results when applicable. Associations with log(pre-treatment TTMV-HPV DNA levels) were evaluated via multivariable linear regression. A commercially available TTMV-HPV DNA test was used.

resultsIn total, 94 patients were included, who were 93% male, with median age of 63 years (interquartile range [IQR] 55-70). Most patients were clinical tumor class cT1 (40%) or cT2 (38%) and clinical nodal class cN1 (77%). Surgical resection was performed in 37% of patients. Median pretreatment TTMV-HPV level was 225 (IQR 46-1132) fragments/mL. Independent associations were found between pretreatment TTMV-HPV levels and clinical nodal staging (P < .001), largest lymph node dimension on pretreatment CT (r = 0.63 [95% confidence interval [CI]: 0.46-1.2]; P < .001) and surgical pathology (r = 0.63 [0.18-1.08; P = .01), number of metastatic nodes on CT (r = 0.52 [0.2-0.84]; P < .001), clinical signs of extranodal extension (r = 1.66 [0.12-3.2]; P = 0.04), and SUV-max of lymph nodes (r = 0.16 [0.05-0.27]; P < 0.001).

conclusionsPre-treatment TTMV-HPV DNA was significantly associated with lymph node disease burden in HPV-associated OPSCC, on pre-treatment CT, PET, and surgical pathology.

Indexed as

DNA, ViralOropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTumor BurdenDNA, ViralHPVnodal diseaseOPSCCTTMV‐HPV DNA

Identifiers

PMID40624873
PMCPMC12461791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.